University of Michigan

Tsrl, Inc.

Xinmin Gan

Alan Robert Saltiel

Hollis Showalter

John J Tesmer

Kim Hutchings

Andy D White

Elke Lipka

Eric Simon

Provided are prodrugs of various therapeutic agents that provide enhanced bioavailability of the therapeutic agent, and methods of treatment conditions in a subject by administration of the one or prodrugs. As provided herein a prodrug includes a therapeutic agent covalently attached to a cap, the cap having a structure according to formula (I) where: Ris a branched or linear substituted or unsubstituted C2-C6 alkyl, alkenyl, or alkynl; X is —S(0)-; Ris a branched or linear substituted or unsubstituted C4-C20 alkyl, alkenyl, or alkynyl; and Ris —H, C3-C5 cycloalkyl, C3-C5 cycloheteroalkyl, —C(CH), —CF, —C(CF), or a substituted or unsubstituted phenyl.

Metabolically stable prodrugs

Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.

Amlexanox analogs

Growing community of inventors

Ann Arbor, MI, United States of America

Xinmin Gan